The ORIGIN trial demonstrated that the use of basal insulin was safe on CV outcomes and cancer occurrence.[9] But Holden et al[10] reported 6484 T2DM patients who progressed to treatment with insulin monotherapy, the adjusted hazard ratio (aHR) in relation to 1-unit increases in insulin dose was 1.54 for all-cause mortality and 1.35 for cancer. Here, INS is linked to cancer.